We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
Read MoreHide Full Article
Key Takeaways
The Medical sector shows strong Q3 trends, with most firms beating earnings and revenue estimates.
Four biotech firms, Alto, Autolus, Ascendis, and Immuneering, match criteria for likely earnings beats.
Each holds positive Earnings ESP and solid ranks, boosting odds of outperforming when results are released.
The third-quarter 2025 reporting cycle of the Medical sector is currently approaching its end. The sector primarily comprises pharma/biotech and medical device companies.
Many pharma giants, like Amgen, Novo Nordisk and Pfizer, reported earnings last week. While results for Amgen and Pfizer were strong on both earnings and sales, both companies also raised their EPS outlook for 2025. However, things did not look good for Novo Nordisk, which reported weaker-than-expected Q3 results. The Danish drugmaker also slashed its guidance outlook for the full year due to the slower growth of its GLP-1 portfolio amid increased availability of compounded alternatives and intensifying competition from arch-rival Eli Lilly.
The Earnings Trends report indicates that as of Nov. 5, nearly 82% of the companies in the Medical sector — representing 92% of the sector’s market capitalization — reported quarterly earnings. While about 92% of participants beat on earnings, around 84% outperformed revenues. Earnings rose over 4% year over year, while revenues increased nearly 11%. Overall, third-quarter earnings and sales are expected to rise 3.0% and 10.5%, respectively, from the year-ago quarter’s reported figures.
Zeroing in on Winners
While most companies in the sector have reported earnings, there are some companies which are yet to report. Out of them, we have highlighted four biotech companies — Alto Neuroscience (ANRO - Free Report) , Autolus Therapeutics (AUTL - Free Report) , Ascendis Pharma (ASND - Free Report) and Immuneering(IMRX - Free Report) — that seem poised to deliver a beat in their upcoming quarterly results.
Earnings ESP is our proprietary methodology for determining the stocks with the best chance to deliver an earnings surprise. It shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener.
Our research shows that the chance of an earnings surprise for stocks with this combination is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
4 Biotech Stocks That Match the Criteria
Alto Neuroscience
Alto is a clinical-stage biotech focused on developing a broad range of novel pipeline therapies targeting neuroscience indications like bipolar depression, major depressive disorder and schizophrenia. The company has an Earnings ESP of +16.41% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for the third quarter is pegged at a loss of 66 cents per share.
ANRO beat on earnings in three of the trailing four quarters and missed the mark once, delivering an average surprise of 4.36%.
A commercial-stage company, Autolus is primarily focused on developing, manufacturing and marketing next-generation T cell therapies targeting cancer and autoimmune diseases. The company has an Earnings ESP of +22.30% and a Zacks Rank #2 at present. The Zacks Consensus Estimate for third-quarter bottom line is pegged at a loss of 23 cents per share.
AUTL beat on earnings in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 6.55%. The company is scheduled to release results on Nov. 12, before the opening bell.
Autolus Therapeutics PLC Sponsored ADR Price and EPS Surprise
The company is a commercial-stage biotech focused on developing and marketing therapies targeting growth disorders and rare endocrine diseases. Ascendis has an Earnings ESP of +34.28% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for third-quarter bottom line is pegged at a loss of 41 cents per share.
ASND beat on earnings in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 11.15%. It is scheduled to report earnings on Nov. 12, after the market closes.
The company is a clinical-stage biotech focused on developing its lead pipeline candidate targeting tumors harboring the RAS mutation. It has an Earnings ESP of +21.62% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for third-quarter earnings is pegged at a loss of 37 cents per share.
IMRX beat on earnings in one of the trailing four quarters, met the mark once, but missed the mark on the other two occasions. It delivered a negative average surprise of 7.82%. The company is scheduled to report earnings on Nov. 12, after the market closes.
Image: Bigstock
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
Key Takeaways
The third-quarter 2025 reporting cycle of the Medical sector is currently approaching its end. The sector primarily comprises pharma/biotech and medical device companies.
Many pharma giants, like Amgen, Novo Nordisk and Pfizer, reported earnings last week. While results for Amgen and Pfizer were strong on both earnings and sales, both companies also raised their EPS outlook for 2025. However, things did not look good for Novo Nordisk, which reported weaker-than-expected Q3 results. The Danish drugmaker also slashed its guidance outlook for the full year due to the slower growth of its GLP-1 portfolio amid increased availability of compounded alternatives and intensifying competition from arch-rival Eli Lilly.
The Earnings Trends report indicates that as of Nov. 5, nearly 82% of the companies in the Medical sector — representing 92% of the sector’s market capitalization — reported quarterly earnings. While about 92% of participants beat on earnings, around 84% outperformed revenues. Earnings rose over 4% year over year, while revenues increased nearly 11%. Overall, third-quarter earnings and sales are expected to rise 3.0% and 10.5%, respectively, from the year-ago quarter’s reported figures.
Zeroing in on Winners
While most companies in the sector have reported earnings, there are some companies which are yet to report. Out of them, we have highlighted four biotech companies — Alto Neuroscience (ANRO - Free Report) , Autolus Therapeutics (AUTL - Free Report) , Ascendis Pharma (ASND - Free Report) and Immuneering (IMRX - Free Report) — that seem poised to deliver a beat in their upcoming quarterly results.
Earnings ESP is our proprietary methodology for determining the stocks with the best chance to deliver an earnings surprise. It shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.
According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be made with the help of the Zacks Stock Screener.
Our research shows that the chance of an earnings surprise for stocks with this combination is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
4 Biotech Stocks That Match the Criteria
Alto Neuroscience
Alto is a clinical-stage biotech focused on developing a broad range of novel pipeline therapies targeting neuroscience indications like bipolar depression, major depressive disorder and schizophrenia. The company has an Earnings ESP of +16.41% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for the third quarter is pegged at a loss of 66 cents per share.
ANRO beat on earnings in three of the trailing four quarters and missed the mark once, delivering an average surprise of 4.36%.
Alto Neuroscience, Inc. Price and EPS Surprise
Alto Neuroscience, Inc. price-eps-surprise | Alto Neuroscience, Inc. Quote
Autolus Therapeutics
A commercial-stage company, Autolus is primarily focused on developing, manufacturing and marketing next-generation T cell therapies targeting cancer and autoimmune diseases. The company has an Earnings ESP of +22.30% and a Zacks Rank #2 at present. The Zacks Consensus Estimate for third-quarter bottom line is pegged at a loss of 23 cents per share.
AUTL beat on earnings in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 6.55%. The company is scheduled to release results on Nov. 12, before the opening bell.
Autolus Therapeutics PLC Sponsored ADR Price and EPS Surprise
Autolus Therapeutics PLC Sponsored ADR price-eps-surprise | Autolus Therapeutics PLC Sponsored ADR Quote
Ascendis Pharma
The company is a commercial-stage biotech focused on developing and marketing therapies targeting growth disorders and rare endocrine diseases. Ascendis has an Earnings ESP of +34.28% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for third-quarter bottom line is pegged at a loss of 41 cents per share.
ASND beat on earnings in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 11.15%. It is scheduled to report earnings on Nov. 12, after the market closes.
Ascendis Pharma A/S Price and EPS Surprise
Ascendis Pharma A/S price-eps-surprise | Ascendis Pharma A/S Quote
Immuneering
The company is a clinical-stage biotech focused on developing its lead pipeline candidate targeting tumors harboring the RAS mutation. It has an Earnings ESP of +21.62% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for third-quarter earnings is pegged at a loss of 37 cents per share.
IMRX beat on earnings in one of the trailing four quarters, met the mark once, but missed the mark on the other two occasions. It delivered a negative average surprise of 7.82%. The company is scheduled to report earnings on Nov. 12, after the market closes.
Immuneering Corporation Price and EPS Surprise
Immuneering Corporation price-eps-surprise | Immuneering Corporation Quote